Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Download All
Learn more about Ki67 testing and learn how to accurately interprete and apply the test results for the optimal selection of therapy for patients with HR-positive, HER2-negative early breast cancer.
Joyce O'Shaughnessy, MD
Program Director
Sara Tolaney, MD, MPH
Program Director
person default
Sunil Badve, MD, FRCPath

ClinicalThought

Are you testing for Ki67 expression levels in patients with early-stage hormone receptor-positive/HER2-negative breast cancer? Read this commentary for a pathologist’s perspective on Ki67 testing.

person default Sunil Badve, MD, FRCPath Released: December 28, 2021

Downloadable Slideset

Download this slideset from a live workshop series to gain more insight into the optimal utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including a review of the latest evidence and practical clinical insights from expert faculty.

Joyce O'Shaughnessy, MD
Program Director
Sara Tolaney, MD, MPH
Program Director
Released: March 4, 2022

On Demand Webcast

In this on-demand webcast from a live webinar, Joyce O’Shaughnessy, MD, reviews the current data supporting the utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including strategies to promote adherence to oral CDK4/6 inhibitors.

Joyce O'Shaughnessy, MD
Program Director
Sara Tolaney, MD, MPH
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 11, 2022 Expired: May 10, 2023
Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
This activity is supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings